Arcus Biosciences Inc., a clinical-stage global biopharmaceutical company, has announced new employment inducement grants for two new employees. The grants include options to purchase a total of 13,400 shares of the company's common stock at an exercise price of $9.02 per share, reflecting the closing price on May 23, 2025. Additionally, the employees were awarded restricted stock units to acquire a total of 13,400 shares of the company's common stock. These equity awards are part of the Company's 2020 Inducement Plan, approved by the Board of Directors in January 2020 under the NYSE's inducement exception rule.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.